



PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB

Complete if Known Substitute for form 1449A/PTO **Application Number** 10/070,569 INFORMATION DISCLOSURE **Filing Date** March 8, 2002 STATEMENT BY APPLICANT **First Named Inventor** Takashi Muramatsu (use as many sheets as necessary) **Art Unit Examiner Name** 1 of Sheet **Attorney Docket Number** SPO-116

			U.S. PATENT D	OCUMENTS	
Examiner Initials*	Cite No. 1	Document Number Number - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U1	US-			
	U2	US-			DE 6
	U3	US-			RECEIVE
	U4	US-			
	U5	US-			
	U6	US-			FEB 0.3 2002
	U19	US-			2003
	U20	US-			TRA
					IECH CENTED 40004

		FOREIGN	PATENT DOCU	JMENTS	CENTEN	1000/2
Examiner Initials*	Cite No. 1	Foreign Patent Document  Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
Nhlh	F1	JP 6-172218 A WAYACLOIN	6-21-1994	Mitsui Toatsu Chemicals		
	F2	JP 6-113898 A a 1/21/02/07/	4-26-1994	Mitsui Toatsu Chemicals		
\V	F3	WO 00/31541 A	6-02-1994	Georgetown University		I
	F4					
	F5					
	F6					
	F7					
	F8					
	F9				<u> </u>	
	F10				I	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Cite No. 1		Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
rus	R1	Nakagaware et al. "Differential Expression of Pleiotrophin and Midkine in Advanced Neuroblastomas" Cancer Research 55(8):1792-1797, 1995.	
anh	R2	Ye et al. "Expression of midkine in the early stage of carcinogenesis in human colorectal cancer" British J. Cancer 79(1):179-184, January 1999.	
	R3		

Examiner Signature	anduri	Date Considered 7	22	2003	
Cignataro	1 3 ( 10 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	Concidence	•		_

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.



PTO/SB/08B (10-01) Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB

**Application Number** 

First Named Inventor

**Filing Date** 

**Group Art Unit** 

respond to a collection of information unless it contains a valid OMB

Complete if Known

10/070,569

1832 , 14

March 8, 2002

Takashi Muramatsu

## Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1 Attorney Docket Number SPO-116

		NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	I A I ITEM (DOOK MAGAZINE JOURNAL SERIAL SYMPOSIUM CATALOG ETC.) MATE DAGEST VOILIME-ISSUE		T²		
any	R1	ARIDOME, K., J. TSUTSUI, S. TAKAO, K. KADOMATSU, M. OZAWA, T. AIKOU, and T. MURAMATSU. "Increased midkine gene expression in human gastrointestinal cancers." <i>Jpn. J. Cancer Res.</i> July, 1995. 86: 655-661.			
$I \wedge I$	R2	GARVER, R.I., D.M. RADFORD, H. DONIS-KELLER, M.R. WICK, and P.G. MILNER. "Midkine and pleiotrophin expression in normal and malignant breast tissue." <i>Cancer</i> . September 1, 1994. 74(5): 1584-1590.			
	R3	IKEMATSU, S., A. YANO, K. ARIDOME, M. KIKUCHI, H. KUMAI, H. NAGANO, K. OKAMOTO, M. ODA, S. SAKUMA, T. AIKOU, H. MURAMATSU, K. KADOMATSU, and T. MURAMATSU. "Serum midkine levels are increased in patients with various types of carcinomas." <i>Br. J. Cancer.</i> 2000. 83(6): 701-706.			
	R4	KOIDE, N., H. HADA, T. SHINJI, K. UJIKE, S. HIRASAKI, Y. YUMOTO, T. HANAFUSA, K. KADOMATSU, H. MURAMATSU, T. MURAMATSU, and T. TSUJI. "Expression of the midkine gene in human hepatocellular carcinomas." <i>Hepato-Gastroenterology</i> . 1999. 46: 3189-3196.			
	R5	KONISHI, N., M. NAKAMURA, S. NAKAOKA, Y. HIASA, M. CHO, H. UEMURA, Y. HIRAO, T. MURAMATSU, and K. KADOMATSU. "Immunohistochemical analysis of midkine expression in human prostate carcinoma." <i>Oncology</i> . 1999. 57: 253-257.			
W	R6	MURAMATSU, H., et al. "Enzyme-linked immunoassay for midkine, and its application to evaluation of midkine levels in developing mouse brain and sera from patients with hepatocellular carcinomas." J. Biochem. 1996. 119: 1171-1175.			
V	R7	TSUTSUI, J., K. KADOMATSU, S. MATSUBARA, A. NAKAGAWARA, M. HAMANOUE, S. TAKAO, H. SHIMAZU, Y. OHI, and T. MURAMATSU. "A new family of heparin-binding growth/differentiation factors: increased midkine expression in Wilms' tumor and other human carcinomas." <i>Cancer Res.</i> 1993. 53: 1281-1285.			
	R8				
	R9				
	R10	DECEIVED			
	R11	RECEIVED DEC 1 1 2002			
	R12	Tech center 1600/2900			
	R13				

Examiner Signature	amtarris	Date Considered 722 2583
Olgitalato		Considered

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.